ECSP034595A - Agonista del receptor alfa activado del proliferador de peroxisomas - Google Patents

Agonista del receptor alfa activado del proliferador de peroxisomas

Info

Publication number
ECSP034595A
ECSP034595A EC2003004595A ECSP034595A ECSP034595A EC SP034595 A ECSP034595 A EC SP034595A EC 2003004595 A EC2003004595 A EC 2003004595A EC SP034595 A ECSP034595 A EC SP034595A EC SP034595 A ECSP034595 A EC SP034595A
Authority
EC
Ecuador
Prior art keywords
group
substituted
alkyl
unsubstituted
hydrogen
Prior art date
Application number
EC2003004595A
Other languages
English (en)
Inventor
Richard Duane Johnston
Nathan Bryan Mantlo
Yanping Xu
Xiaodong Wang
Michael John Martinelli
Daniel Ray Mayhugh
David Scott Coffey
Cano Ivan Collado
Paredes Cristina Garcia
Jeffrey Thomas Vicenzi
Samuel J Dominianni
Garret Jay Etgen
Christopher Randall Schmid
Michael Edward Tourneau
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP034595A publication Critical patent/ECSP034595A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/22—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having nitrogen atoms of amidino groups further bound to nitrogen atoms, e.g. hydrazidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C07C281/04—Compounds containing any of the groups, e.g. carbazates the other nitrogen atom being further doubly-bound to a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cultivation Of Plants (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

(c) R2 es Ho un grupo sustituido o insustituido seleccionado del grupo constituido por alquilo C1-C6, alilo C1-C6, arilalquilo Co-C4, heteroari-alquilo C0-C4, sulfonamida, amida, OR10 y cicloalquilo C3-C6; (d) X es un alquileno C1-C5 de unión opcionalmente sustituido en el que un átomo de carbono del elemento de unión puede estar sustituido con O, NH o S; (e) Y es C, O, S, NH o un enlace sencillo; y (f) E se selecciona del grupo constituido por hidrógeno, C (R3) (R4) A, A, sustituido o insustituido, seleccionado del grupo constituido por hidrógeno, C(R3) (R4) A, A, sustituido o insustituido , seleccionado del grupo constituido por (CH2)n COOR19, alquilo C1-C4, aminoarilo y aminoalquilo C1-C4 y en la que n es 0, 1, 2 o 3, A es un grupo funcional seleccionado del grupo constituido por carboxilo, alquilnitrilo C1-C3, carboxamida, sulfonamida sustituida o insustituida y tetrazol sustituido o insustituido; R3 es H, alquilo C1-C5 saturado o insaturado, alcoxi C1-C5, y R4 es H, halo, un grupo sustituido o insustituido seleccionado entre alquilo C1-C5, alcoxi C1-C5, cicloalquilo C3-C6, arilalquilo C0-C4 y fenilo o R3 y R4 se conbinan para formar un cicloalquilo C3-C4; R19 se selecciona del grupo constituido por hidrógeno, arilmetilo opcionalmente sustituido y alquilo C1-C4 opcionalmente sustituido; R8 se selecciona independientemente del grupo constituido por hidrógeno, alquilo C1-C4, alquilenilo C1-C4 y halo; R9 se selecciona independientemente del grupo constituido por hidrógeno, alquilo C1-C4, alquilenilo C1- C4, halo, arilo sustituido o insustituido, arilalquilo C1-C4 sustituido o insustituido, heteroarilo sustituido o insustituido, slilo V1-C6 y =R10; y R10 se selecciona independientemente del grupo constituido por hidrógeno y alquilo C1-C4.
EC2003004595A 2000-11-10 2003-05-08 Agonista del receptor alfa activado del proliferador de peroxisomas ECSP034595A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24731700P 2000-11-10 2000-11-10

Publications (1)

Publication Number Publication Date
ECSP034595A true ECSP034595A (es) 2003-06-25

Family

ID=22934453

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004595A ECSP034595A (es) 2000-11-10 2003-05-08 Agonista del receptor alfa activado del proliferador de peroxisomas

Country Status (35)

Country Link
US (3) US7304062B2 (es)
EP (1) EP1335908B1 (es)
JP (1) JP4243101B2 (es)
KR (1) KR100839705B1 (es)
CN (1) CN1479728A (es)
AR (1) AR031305A1 (es)
AT (1) ATE386026T1 (es)
AU (3) AU2859202A (es)
BR (1) BR0114986A (es)
CA (1) CA2421154A1 (es)
CY (1) CY1107388T1 (es)
CZ (1) CZ20031283A3 (es)
DE (1) DE60132799T2 (es)
DK (1) DK1335908T3 (es)
EA (1) EA006920B1 (es)
EC (1) ECSP034595A (es)
ES (1) ES2300378T3 (es)
HK (1) HK1058790A1 (es)
HR (1) HRP20030365A2 (es)
HU (1) HUP0301655A2 (es)
IL (2) IL154840A0 (es)
MX (1) MXPA03004141A (es)
MY (1) MY157884A (es)
NO (1) NO20032059L (es)
NZ (1) NZ524569A (es)
PE (1) PE20020693A1 (es)
PL (1) PL362692A1 (es)
PT (1) PT1335908E (es)
SI (1) SI1335908T1 (es)
SK (1) SK5412003A3 (es)
SV (1) SV2003000727A (es)
TW (1) TW200716572A (es)
UA (1) UA82048C2 (es)
WO (1) WO2002038553A2 (es)
ZA (1) ZA200302517B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002347985A1 (en) 2001-11-15 2003-06-10 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
US7220880B2 (en) 2002-06-19 2007-05-22 Eli Lilly And Company Amide linker peroxisome proliferator activated receptor modulators
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
FR2866339B1 (fr) * 2004-02-18 2006-05-05 Pf Medicament Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
KR100803481B1 (ko) * 2004-07-27 2008-02-14 에프. 호프만-라 로슈 아게 비-뉴클레오사이드 역전사효소 억제제로서의벤질트라이아졸론 화합물
SG148179A1 (en) * 2004-07-27 2008-12-31 Hoffmann La Roche Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
NZ552501A (en) * 2004-08-11 2010-03-26 Kyorin Seiyaku Kk Novel cyclic aminobenzoic acid derivative
WO2006068199A1 (ja) * 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
TW200640453A (en) * 2005-01-28 2006-12-01 Lilly Co Eli Formulations and dosing regimen for PPAR-α modulators
FR2882750B1 (fr) * 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
US20090036489A1 (en) * 2005-03-22 2009-02-05 Masahiro Nomura Novel Cyclic Aminophenylalkanoic Acid Derivative
CN101180280A (zh) * 2005-03-24 2008-05-14 弗·哈夫曼-拉罗切有限公司 作为杂环逆转录酶抑制剂的1,2,4-三唑-5-酮化合物
WO2007126043A1 (ja) * 2006-04-27 2007-11-08 Mitsubishi Tanabe Pharma Corporation チアゾール環を含むカルボン酸誘導体の医薬用途
MX2009008998A (es) * 2007-02-23 2009-09-02 Lilly Co Eli Moduladores del receptor activado por proliferador de peroxisoma.
BRPI0809617A2 (pt) 2007-03-29 2014-09-16 Hoffmann La Roche Inibidores não-nucleosídicos da transcriptase reversa
WO2010002712A2 (en) * 2008-06-30 2010-01-07 3M Innovative Properties Company Method of crystallization
CN101643451B (zh) * 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
JP5357894B2 (ja) 2008-12-01 2013-12-04 田辺三菱製薬株式会社 チアゾール環を含むカルボン酸誘導体およびその医薬用途
US8575430B2 (en) * 2010-03-02 2013-11-05 Nunhems, B.V. Hybrid artichoke variety NUN 4006 AR
US20110167512A1 (en) * 2009-03-02 2011-07-07 Nunhems B.V. Hybrid artichoke variety nun 4006 ar
DE102010001064A1 (de) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
US20100245582A1 (en) * 2009-03-25 2010-09-30 Syclipse Technologies, Inc. System and method of remote surveillance and applications therefor
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US8648233B2 (en) * 2010-09-20 2014-02-11 Nunhems B.V. Hybrid artichoke variety NUN 4021 AR
US8669420B2 (en) 2012-02-29 2014-03-11 Nunhems B.V. Hybrid artichoke variety NUN 4060 AR
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
CN104918922B (zh) 2012-12-20 2017-04-26 因森普深2公司 三唑酮化合物及其用途
CN105579440A (zh) * 2013-09-06 2016-05-11 因森普深2公司 三唑酮化合物及其应用
RU177130U1 (ru) * 2017-11-29 2018-02-09 Владимир Алексеевич Коннов Плита изоляционная облицовочная
CN115398657A (zh) 2020-04-10 2022-11-25 松下知识产权经营株式会社 热电转换元件、热电转换组件、接合材料和热电转换元件的制造方法
CN112774869B (zh) * 2020-12-25 2022-09-16 厦门紫金矿冶技术有限公司 黄铁矿抑制剂及其制备和在铜铅锌多金属硫化矿中的应用
CN114853686B (zh) * 2021-08-23 2023-06-20 中国药科大学 三氮唑酮类化合物及其医药用途
CN115894379A (zh) * 2022-01-20 2023-04-04 中国药科大学 海因类化合物及其医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090283A1 (en) 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
DE19517505A1 (de) * 1995-05-12 1996-11-14 Bayer Ag Sulfonylamino(thio)carbonyltriazolin(thi)one mit Aryloxy- oder Arylthio-Substituenten
WO1997015567A1 (de) 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
ID23989A (id) * 1997-10-17 2000-06-14 Yamanouchi Pharma Co Ltd Turunan-turunan amida atau garam-garamnya
DE69828445D1 (de) 1998-04-23 2005-02-03 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
USPP14578P2 (en) * 2002-09-23 2004-03-09 Plant Sciences, Inc. Artichoke plant named ‘PS-MSC0003’

Also Published As

Publication number Publication date
MXPA03004141A (es) 2003-08-19
NZ524569A (en) 2006-05-26
US7868225B2 (en) 2011-01-11
TW200716572A (en) 2007-05-01
HRP20030365A2 (en) 2003-08-31
NO20032059D0 (no) 2003-05-08
PE20020693A1 (es) 2002-08-05
AU2006202811A1 (en) 2006-07-20
US20090062358A1 (en) 2009-03-05
IL154840A (en) 2009-09-22
PL362692A1 (en) 2004-11-02
AU2859202A (en) 2002-05-21
HK1058790A1 (en) 2004-06-04
AU2002228592B8 (en) 2006-08-24
EA006920B1 (ru) 2006-04-28
KR20030048133A (ko) 2003-06-18
EP1335908B1 (en) 2008-02-13
CY1107388T1 (el) 2012-12-19
UA82048C2 (uk) 2008-03-11
CZ20031283A3 (cs) 2003-09-17
MY157884A (en) 2016-08-01
SI1335908T1 (sl) 2008-08-31
PT1335908E (pt) 2008-05-08
AR031305A1 (es) 2003-09-17
SK5412003A3 (en) 2004-01-08
KR100839705B1 (ko) 2008-06-19
EA200300558A1 (ru) 2004-02-26
ES2300378T3 (es) 2008-06-16
CA2421154A1 (en) 2002-05-16
SV2003000727A (es) 2003-01-13
US20040102500A1 (en) 2004-05-27
DE60132799T2 (de) 2009-03-19
DK1335908T3 (da) 2008-06-02
BR0114986A (pt) 2003-09-23
ZA200302517B (en) 2004-06-30
CN1479728A (zh) 2004-03-03
AU2002228592B2 (en) 2006-04-27
IL154840A0 (en) 2003-10-31
JP4243101B2 (ja) 2009-03-25
US7304062B2 (en) 2007-12-04
ATE386026T1 (de) 2008-03-15
NO20032059L (no) 2003-06-24
DE60132799D1 (de) 2008-03-27
JP2004513166A (ja) 2004-04-30
WO2002038553A2 (en) 2002-05-16
US20090044299A1 (en) 2009-02-12
WO2002038553A3 (en) 2003-05-01
EP1335908A2 (en) 2003-08-20
HUP0301655A2 (hu) 2003-12-29

Similar Documents

Publication Publication Date Title
ECSP034595A (es) Agonista del receptor alfa activado del proliferador de peroxisomas
CO5611131A2 (es) Derivados de 5-feniltiazol y su uso como inhibidores de pi3 cinasa
AR055360A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
ES2192520T3 (es) Composicion farmaceutica.
PE105499A1 (es) Composiciones anagelsicas de imidazolidin-2,4-diona sustituida conjuntamente con al menos uno de opioides, tramadol y no opioides
AR034405A1 (es) Composiciones farmaceuticas que contienen derivados de 3-amino-azetidina, los nuevos derivados y su preparacion
AR041867A1 (es) Agente para prevenir o tratar neuropatia
PE20040451A1 (es) Activadores cicloalquil sustituidos y cicloalquil oxigenados de glucoquinasa
ES2571327T3 (es) Composiciones plaguicidas
AR048055A1 (es) Derivados de pirimidina como inhibidores de dipeptidil peptidasa
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
PE20060427A1 (es) Derivados de pirazol como inhibidores de la union del glucagon y composiciones
PE20001317A1 (es) N-(glicilo sustituido)-2-cianopirrolidinas como inhibidores de dpp-iv
CO5640155A2 (es) Derivados de pirido[2,1-a]isoquinolina como inhibidores de la dpp-iv
CO5450245A1 (es) Compuestos quimicos con actividad doble, procedimientos para su preparacion y composiciones farmaceuticas
AR045782A2 (es) Derivados de piperidina que tienen actividad farmaceutica
AR044629A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
AR064521A1 (es) Activador de glucoquinasa
PE20080154A1 (es) Derivados de benzamida como moduladores de hidroxiesteroide deshidrogenasas
AR098744A2 (es) Composición catártica
PE20080843A1 (es) Inhibidores de renina y metodo para su utilizacion
BR112012007069A2 (pt) derivado de fenol
DK1392291T3 (da) Tripeptidylpeptidaseinhibitorer
AR065850A1 (es) Composicion farmaceutica solida que comprende un derivado de benzimidazol-7-carboxilato y un agente de control de ph
CO4930274A1 (es) Tiazol bencenosulfonamidas como agonistas b3 para el trata- miento de la diabetes y la obesidad